Larimar Therapeutics, Inc. (LRMR) Cash Flow Statement
Larimar Therapeutics, Inc. (LRMR) generated -$155.9M of operating cash flow over the twelve months to 2026-06-30, spent $153000 on capital expenditure and had free cash flow of -$156.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LRMRLarimar Therapeutics, Inc.Follow LRMR — free
—
Price chart with a free account
- Market cap
- 244.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 11 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -28.2 | -59.6 | -52.0 | -43.8 | -51.5 | -22.7 | -42.2 | -42.1 | -27.6 | -33.5 | -70.8 | -113.2 | -155.9 | |
| Capital expenditure | 0.1 | 0.6 | 0.7 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.1 | 0.2 | 0.5 | 0.1 | -0.2 | |
| Free cash flow | -28.3 | -60.1 | -52.6 | -43.8 | -51.6 | -22.8 | -42.3 | -42.4 | -27.7 | -33.6 | -71.3 | -113.3 | -156.1 | |
| Stock-based compensation | — | — | 10.1 | 8.3 | 9.6 | 0.1 | 2.2 | 5.5 | 6.6 | 7.6 | 8.8 | 7.0 | — |
USD millions · SEC XBRL
Larimar Therapeutics, Inc. — questions
- What is Larimar Therapeutics, Inc.'s operating cash flow?
- -$155.9M over the twelve months to 2026-06-30.
- How much does Larimar Therapeutics, Inc. spend on capital expenditure?
- $153000 over the twelve months to 2026-06-30.
- What is Larimar Therapeutics, Inc.'s free cash flow?
- -$156.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Larimar Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.